Resources

This circular is to advise stakeholders of the publication of a high level summary and individual submissions.

The document contains advice on the third and final reduction of benefits for Cardiac Implantable Electronic Devices (CIED) effective 1 July 2025.

This page lists the medical devices and human tissue products private health insurers must pay benefits for to the patients who have appropriate insurance policies. The latest version of the Prescribed List is effective from 1 July 2025.

This document provides a high-level summary of stakeholder feedback received in response to Consultation Paper 9 – CIED and the cost of technical support services.

We have developed a Prescribed List Post-listing Review Framework that is used to guide the post-listing review process as part of the Prescribed List Reforms.

The interim evaluation report covers the period from May 2021 to June 2024 and reports on whether the reforms being implemented and achieving the expected outcomes.

This report is to provide an analysis of stakeholder feedback received.

This document provides information on the Regional, Rural and Remote Home Care Workforce Support Program, and is designed for grant applicants and recipients.

This evaluation focuses on the Prostheses List reforms, which are running from 1 July 2021 to 30 June 2025. Evaluation of these reforms will determine whether the reform program is being implemented as intended.

This list includes details of the 26 billing codes for medicines and related accessories scheduled to be removed from Part D of the Prescribed List effective 1 November 2024.

This report provides an analysis of stakeholder feedback received in response to the Consultation Paper on the proposed Compliance, Assurance and Information sharing measures for the Prescribed List (PL).

This report provides an analysis of stakeholder feedback received in response to the consultation paper on the proposed measure: Prescribed List (PL) gifts, benefits and discounts reporting requirements.

This report provides an analysis of stakeholder feedback received in response to the consultation paper on the proposed measure: alignment of amount charged for supply of a device with corresponding PL benefit.

This report is a review of surgical guides and biomodels currently listed on the Prostheses List.

These documents contain advice on the Prescribed List (PL) adjusted benefits, resulting from the public benchmarking undertaken by the Independent Health and Aged Care Pricing Authority (IHACPA). The documents outline the November 2023 PL benefits, and the adjusted benefits effective 1 July 2024.

This cost recovery implementation statement describes how the Department of Health and Aged Care recovers the costs of administering the Prescribed List of Benefits for Medical Devices and Human Tissue Products.

Terms of reference for the Medical Devices and Human Tissue Advisory Committee.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6a - Listing Criteria.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6a – Listing Criteria.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6b Cost Recovery Arrangements.

The below document outlines Prescribed List compliance obligations for relevant stakeholders and the Australian Government.

The below report provides analysis of stakeholder feedback to the proposed Prostheses List Compliance Strategy. The submission period for responses was between 14 September and 21 October 2022.

The below data documents detail cardiac implantable electronic devices (CIEDs) that will have their Prostheses List (PL) benefits reduced by 40% of the gap on 1 July 2023.

This report details supplementary advice on bundling arrangements for General Use Items on the Prostheses List.